Innovative AI software for the detection of pancreatic diseases: first-in-human application successful
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
ACHENMUEHLE, Germany -- Businesswire -- Diseases of the pancreas can have serious consequences for patients and are difficult to diagnose. Early detection is crucial for the patient‘s chance of survival. In Europe today, more than 90 percent of patients die of pancreatic cancer within the first five years after diagnosis. The Medi-Globe Group, a leading international MedTech company based in Achenmühle, Bavaria, will, in cooperation with the French Institut Hospitalo-Universitaire (IHU) Strasbourg, develop the world’s first AI software for the detection of diseases of the pancreas in endoscopic ultrasound (EUS) examination. The key technology here is artificial intelligence. As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications.
“The new software has the potential to revolutionize the diagnosis of pancreatic diseases and, above all, the diagnosis of pancreatic cancer. That would be a dream for society as a whole and an important milestone in medicine and for medical technology,” says Prof. Dr. Leonardo Sosa Valencia, one of the leading gastroenterologists in the world and a top expert in the field of pancreatic disease detection.
The AI software brings together the clinical experience of the world’s most experienced gastroenterologists. It bundles the knowledge from countless EUS examinations of the pancreas in an algorithm and transforms it into use in endoscopic ultrasound. The expert knowledge is used to train a neural network according to the deep learning method. For the diagnosis, it is crucial to recognize pathologically altered areas in the pancreas at an early stage so that a fine needle biopsy can accurately take tissue samples for further analyses and as basis for therapy decisions.
“With the AI software, in the future we will be able to provide gastroenterologists with a virtual expert and give them the opportunity to significantly improve the diagnostics that determine therapy. Very good results have already been achieved in the first clinical applications. Small lesions were detected, even in complex cases. This gives the treating physicians and, above all, the patients great hope for improvement of patient care in the medium term,” says Dr. Markus Schönberger, Director of Business Development at the Medi-Globe Group.
Learn more about Medi-Globe Group at: https://medi-globe-group.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005559/en/
이 뉴스는 기업·기관·단체가 뉴스와이어를 통해 배포한 보도자료입니다.
출처:Medi-Globe Group
보도자료 통신사 뉴스와이어(www.newswire.co.kr) 배포
Copyright © 뉴스와이어. 무단전재 및 재배포 금지.
- 기아, 더 기아 EV3 티저 공개 - 뉴스와이어
- 아이클레보, 가정의 달 맞이 로봇청소기 시크릿 쿠폰 이벤트 진행 - 뉴스와이어
- LIG넥스원, 말레이시아 방산전시회 ‘DSA 2024’ 참가 - 뉴스와이어
- 아디다스 오리지널스, 새로운 시즈널 컬러웨이의 SS24 ‘SL 72’ 출시 - 뉴스와이어
- 한화큐셀 ‘솔라 허브’ 카터스빌 신 공장 가동 본격 개시 - 뉴스와이어
- 플러스엑스, 디자인과 실용성 모두 만족시키는 카드홀더 ‘듀얼프레임 2.0’ 출시 - 뉴스와이어
- 마인퍼퓸랩, 퍼스트 노트 라인 향수 5종 출시 - 뉴스와이어
- hy, 체내 흡수율 높인 ‘브이푸드 리포좀 비타민C’ 출시 - 뉴스와이어
- 삼성전자, 국내 최대 크기 114형 마이크로 LED 앞세워 초프리미엄 TV 시장 공략 - 뉴스와이어
- 캐나다 BC주 한국대표부, 국내 최대 규모 ‘BIO KOREA 2024’ 참가 - 뉴스와이어